而在此次会议上,loana Agache教授及其团队提出PICO 2(图1):Is as-needed ICS/formoterol (single inhaler) without maintenance treatment the preferred treatment compared to as-needed SABA without maintenance treatment in adult/adolescent patients with mild asthma,讲述研究结果,并结合最佳科学证据为轻度哮喘患者...
让我们看看CHEST杂志近期发表的一篇述评ICS/Beta2-Agonist Reliever Therapy in Adolescents and Adults With Asthma[2],针对相关问题的讨论和分析。 推荐ICS/福莫特罗作为首选缓解剂的证据与使用特点(表 1) 表1. ICS/福莫特罗作为缓解剂的现有证据及...
为防止咳嗽变异性哮喘(Cough Variant Asthma,简称CVA)发展为典型哮喘,早期使用吸入性糖皮质激素(ICS)被认为是有效的治疗手段之一。CVA是一种非典型哮喘类型,其主要症状表现为长期慢性咳嗽,而并非常见的喘息、胸闷等哮喘典型症状。由于咳嗽变...
5.https://ginasthma.org/. 6.Kearns N,Williams M, Bruce P, et al. Single dose of budesonide/formoterol turbuhaler compared to salbutamol pMDI for speed of bronchodilator onset in asthma: a randomised cross-over trial. Thorax. 2022 Jul 18; Online ahead of print. doi: 10.1136/thorax-2022-2...
[8]Fujita K, Kasayama S, Hashimoto J, et al. Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. J Bone Miner Res 2001; 16:782.[9]2020版中国糖皮质激素性骨质疏松症防治专家共识[J].中华内科杂志,2021,60(01):13-21.作者：北京天坛...
[7]Gerber AN. Measuring safety of inhaled corticosteroids in asthma. Ann Allergy Asthma Immunol. 2016 Dec;117(6):577-581. [8] Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzzi A, Santus P, Scichilone N, Paggiaro P. Differences in the efficacy and safety among inhaled...
美国《变态反应、哮喘和免疫学年鉴》于2005年1月24日发表了START ( inhaled SteroidTreatment As Regular Therapy in early asthma,早期哮喘常规吸入糖皮质激素进行治疗) 研究的最新结果,研究结果给出了吸入糖皮质激素布地奈德(budesonide,Pulmicort,商品名普米克)为期3年的安全治疗数据。以往的研究发现,无论对于成人还是...
[6]Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study [published correction appears in Lancet Respir Med. ...
文献: 《儿童支气管哮喘诊断与防治指南(2016年版)》及2017年GINA指南(The Global Initiative for Asthma) 陈育智:《儿童支气管哮喘的诊断及治疗》(第3版) 崔永耀:常用吸入性糖皮质激素药理学特性浅谈,临床儿科杂志,第37卷第9期718-720页
美国《变态反应、哮喘和免疫学年鉴》于2005年1月24日发表了START ( inhaled Steroid Treatment As Regular Therapy in earl提于流展州课精取张y asthma,早期哮喘常规吸入糖皮质激素进行治疗)化汉清建修研究的最新结果,研究结果给出了吸入糖皮质激素布地奈德(budesonide,Pulmicort,商品名普米克)为期3年的安全治疗数据...